These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26767544)

  • 41. Investigation of the safety and accuracy of intraoperative gamma probe directed biopsy of bone scan detected rib abnormalities in prostatic adenocarcinoma.
    Thurman SA; Robinson LA; Ahmad N; Pow-Sang JM; Lockhart JL; Seigne J
    J Urol; 2003 Apr; 169(4):1341-4. PubMed ID: 12629356
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone.
    Wu SL; Jones E; Gulley JL; Arlen PM; Chen CC; Figg WD; Dahut WL
    BJU Int; 2007 Mar; 99(3):525-8. PubMed ID: 17155971
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.
    Oyama N; Miller TR; Dehdashti F; Siegel BA; Fischer KC; Michalski JM; Kibel AS; Andriole GL; Picus J; Welch MJ
    J Nucl Med; 2003 Apr; 44(4):549-55. PubMed ID: 12679398
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
    Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
    Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
    [TBL] [Abstract][Full Text] [Related]  

  • 45.
    Schmidkonz C; Hollweg C; Beck M; Reinfelder J; Goetz TI; Sanders JC; Schmidt D; Prante O; Bäuerle T; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
    Prostate; 2018 Jan; 78(1):54-63. PubMed ID: 29105797
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
    Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bone scanning--who needs it among patients with newly diagnosed prostate cancer?
    Hirobe M; Takahashi A; Hisasue S; Kitamura H; Kunishima Y; Masumori N; Iwasawa A; Fujimori K; Hasegawa T; Tsukamoto T
    Jpn J Clin Oncol; 2007 Oct; 37(10):788-92. PubMed ID: 17911377
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker.
    Leisser A; Pruscha K; Ubl P; Wadsak W; Mayerhöfer M; Mitterhauser M; Hacker M; Kramer G; Shariat S; Karanikas G; Hartenbach M; Haug AR
    Prostate; 2015 Nov; 75(15):1760-7. PubMed ID: 26282590
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
    Yu EY; Duan F; Muzi M; Deng X; Chin BB; Alumkal JJ; Taplin ME; Taub JM; Herman B; Higano CS; Doot RK; Hartfeil D; Febbo PG; Mankoff DA
    J Nucl Med; 2015 Mar; 56(3):354-60. PubMed ID: 25635138
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy.
    Okotie OT; Aronson WJ; Wieder JA; Liao Y; Dorey F; DeKERNION JB; Freedland SJ
    J Urol; 2004 Jun; 171(6 Pt 1):2260-4. PubMed ID: 15126798
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.
    Rowe SP; Macura KJ; Ciarallo A; Mena E; Blackford A; Nadal R; Antonarakis ES; Eisenberger MA; Carducci MA; Ross AE; Kantoff PW; Holt DP; Dannals RF; Mease RC; Pomper MG; Cho SY
    J Nucl Med; 2016 Jan; 57(1):46-53. PubMed ID: 26493203
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The improved accuracy of planar bone scintigraphy by adding single photon emission computed tomography (SPECT-CT) to detect skeletal metastases from prostate cancer.
    McLoughlin LC; O'Kelly F; O'Brien C; Sheikh M; Feeney J; Torreggiani W; Thornhill JA
    Ir J Med Sci; 2016 Feb; 185(1):101-5. PubMed ID: 25394725
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
    Barichello M; Gion M; Bonazza A; Delli Ponti US; Bolgan A; Contemori GP; Barioli P; Capitanio G; Pecori B; Omacini S
    Eur Urol; 1995; 27(4):295-300. PubMed ID: 7544735
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?
    Heinisch M; Dirisamer A; Loidl W; Stoiber F; Gruy B; Haim S; Langsteger W
    Mol Imaging Biol; 2006; 8(1):43-8. PubMed ID: 16315004
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prostate-specific antigen detected prostate cancer: pathological characteristics of ultrasound visible versus ultrasound invisible tumors.
    Ferguson JK; Bostwick DG; Suman V; Zincke H; Oesterling JE
    Eur Urol; 1995; 27(1):8-12. PubMed ID: 7538082
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incidental diagnosis of a PSA-negative prostate cancer by 18FDG PET/CT in a patient with hypopharyngeal cancer.
    Bucerius J; Ahmadzadehfar H; Hortling N; Joe AY; Palmedo H; Biersack HJ
    Prostate Cancer Prostatic Dis; 2007; 10(3):307-10. PubMed ID: 17353915
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Carcinoma of the prostate: correlation between local staging and systemic progression].
    Rosi P; Marzi M; Mearini E; Bracarda S; Valli PP; Petroni PA; Porena M
    Arch Ital Urol Androl; 1996 Dec; 68(5 Suppl):91-5. PubMed ID: 9162385
    [TBL] [Abstract][Full Text] [Related]  

  • 60. (18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy.
    Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
    World J Urol; 2015 Nov; 33(11):1749-52. PubMed ID: 25824540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.